Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating ...
Ironwood Pharmaceuticals (NASDAQ:IRWD) executives highlighted stronger demand trends for LINZESS, a revamped pricing approach ...
Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...
Shares of Ironwood Pharmaceuticals (IRWD) added ~31% on Friday to hit a new 52-week high after the company set its 2026 revenue outlook ahead of Street forecasts, citing higher net sales from Linzess, ...
Zacks Investment Research on MSN
Will Linzess continue to aid IRWD's top line in 2026 after a soft Q4?
Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged ...
On Nov. 10, Ironwood reported solid third-quarter results, beating estimates for both earnings and sales, backed by the high demand for its sole marketed product, Linzess (linaclotide). Concurrently, ...
Ironwood Pharmaceuticals expects revenue to rise next year, boosted in part by higher sales of Linzess, its drug used to treat irritable bowel syndrome and constipation. The Boston biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results